TecMed, Inc., a privately held intellectual property (IP) company focused on non-invasive blood glucose management, specializes in IP which allows for increased accuracy, reliability and cost effectiveness in blood glucose measurement. The early designs incorporating our core technology and patented scientific principles have consistentlydemonstrated precision in measurement far superior to current measurement devices and technologies. Our core technology began as The Sentinel, a non-invasive consumer glucose measurement device. This technology led into the development and refinement of IP designed specifically for automated blood glucose measurement before, during and after surgical procedures and in critical care units. Research consistently shows that properly managed blood sugar reduces healthcare costs and improves patient outcomes. Today, there are no patient monitoring solutions that provide this data with sufficient accuracy, immediacy, or frequency to achieve necessary blood sugar goals. Moreover, current methods are labor intensive, expensive, and lack the accuracy that our IP provides. In fact, the accuracy of TecMed's patented and patent pending clinical measurement IP has been demonstrated in more than 30 human trials. In this unserved global market, currently valued at nearly $3B, we are the only organization that has met the current US government regulatory specifications for glucose measurement accuracy in critical care environments. Over 370 shareholders have invested nearly $58M in the creation and refinement of our core technology for utilization in this $15B industry. As we transition from research and development to marketing, we are actively seeking commercialization partners. Our IP for non-invasive consumer, automated clinical patient, and other medical measurement and monitoring designs are ready to be transferred to others for utilization in adaptive medical device design development, manufacturing and monetization.

Biotechnology

TecMed, Inc.

Org chart

Teams

Similar companies